By now, most P&T readers are familiar with the clinical efficacy of the low-molecular-weight (LMW) heparins. Indeed, these new compounds are being prescribed in many settings—from acute coronary syndrome to the prevention and therapy of deep venous thrombosis (DVT). LMW heparins are being given in the outpatient setting through supervised programs coupled with intensive patient [...]

Continue reading " The Paradox of Low-Molecular-Weight Heparins "